In this episode, Dr. Fernando Vieira, CSO at the ALS Therapy Development Institute (ALS TDI), joins us to discuss Copper ATSM (CuATSM)clinical trials. CuATSM is a small molecule drug sponsored by the company Collaborative MedicinalDevelopment (CMD). They recently completed enrollment of a small, Phase 1 clinical trial in Australia.

You can access all episodes of the Endpoints Podcast for free by visiting www.als.net/endpoints and registering.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.